on July 29, 2004
Published online before print July 29, 2004, doi: 10.1161/01.ATV.0000141045.49616.6f
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 21, 2004
Accepted on July 20, 2004
Antimonocyte Chemoattractant Protein-1 Gene Therapy Attenuates Graft Vasculopathy
Akio Saiura ;
From the Departments of Surgery (A.S., M.M.) and Cardiovascular Medicine (M.S., M.W., R.N.), University of Tokyo, Graduate School of Medicine, Japan; and the Department of Cardiovascular Medicine (K.H., S.K., K.E.), University of Kyushu, Graduate School of Medicine, Fukuoka, Japan.
* To whom correspondence should be addressed. E-mail: msata-tky{at}umin.ac.jp.
Objective--Accelerated coronary arteriosclerosis remains a major problem in the long-term survival of cardiac transplant recipients. However, the pathogenesis of graft vasculopathy is poorly understood, and there is no effective therapy. Transplant arteriosclerosis is characterized by early mononuclear cell attachment on the transplanted vessel followed by development of concentric neointimal hyperplasia. Early and persistent expression of monocyte chemoattractant protein-1 (MCP-1) in cardiac allografts has been implicated for the pathogenesis of transplant arteriosclerosis.
Methods and Results--We investigated whether anti-MCP-1 gene therapy can inhibit the development of intima hyperplasia in a mouse model of cardiac transplantation. Either the dominant-negative form of MCP-1 (7ND) or control vector was transfected into the skeletal muscles of B10.D2 mice. Cardiac allografts from DBA/2 mice were transplanted heterotopically into B10.D2 mice. 7ND gene transfer was associated with a significant reduction of the number of mononuclear cells accumulating in the lumen of the graft coronary arteries at 1 week and an attenuation of the development of the lesion at 8 weeks (intima/media ratio 0.79±0.05 versus 0.48±0.04).
Conclusions--The MCP-1/CCR2 signaling pathway plays a critical role in the pathogenesis of graft vasculopathy. This new anti-MCP-1 gene therapy might be useful to treat graft vascular disease.
Key words: cardiac transplantation • graft arteriosclerosis • MCP-1 • CCR2 • chemokine
This article has been cited by other articles:
 |
|
 |
|
  G. Vassalli, M.-E. Roehrich, P. Vogt, G. B. Pedrazzini, F. Siclari, T. Moccetti, and L. K. von Segesser Modalities and future prospects of gene therapy in heart transplantation Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 1036 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schober Chemokines in Vascular Dysfunction and Remodeling Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1950 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schepers, D. Eefting, P.I. Bonta, J.M. Grimbergen, M.R. de Vries, V. van Weel, C.J. de Vries, K. Egashira, J.H. van Bockel, and P.H.A. Quax Anti-MCP-1 Gene Therapy Inhibits Vascular Smooth Muscle Cells Proliferation and Attenuates Vein Graft Thickening Both In Vitro and In Vivo Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2063 - 2069. [Abstract] [Full Text] [PDF]
|
|